141
Views
26
CrossRef citations to date
0
Altmetric
Research Article

Insulin glargine: long-acting basal insulin analog for improved metabolic control

Pages 31-37 | Published online: 22 Sep 2008
 

SUMMARY

The primary aim of insulin therapy is to replace endogenous insulin secretion in patients with type 1 or type 2 diabetes in a physiologically sound manner, mimicking normal secretion patterns to adequately regulate glucose metabolism. The currently available human insulins for basal therapy - neutral protamine Hagedorn (NPH),Lente* and Ultralente – and analogs such as insulin glargine, differ in pharmacokinetic properties. Clinical trial data indicate that insulin glargine may satisfy basal insulin requirements, with an improved safety profile relative to other available insulins used for basal supplementation. This review describes the eunique pharmacokinetic properties and clinical efficacy of insulin glargine.

* Lente is a registered trademark of Novo Nordisk Pharmaceuticals, Bagsværd, Denmark

† Ultralente is a registered trademark of Eli Lilly & Co, Indianapolis, IN, USA

Notes

* Lente is a registered trademark of Novo Nordisk Pharmaceuticals, Bagsværd, Denmark

† Ultralente is a registered trademark of Eli Lilly & Co, Indianapolis, IN, USA

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.